The potential for prostate cancer immunotherapy.
The components of an effective immune response have been elucidated in recent years. An understanding of the dysfunctional immune response in cancer in one or more of these components has lead to a variety of immunotherapeutic approaches. These therapeutic strategies are designed to stimulate dendritic cell (DC) proliferation, promote antigen uptake and processing, stimulate an effector cell response via direct antigen presentation or target tumor cells via antibody therapy. Many approaches in prostate cancer have demonstrated successful induction of the desired immune response. Limited clinical success has also been seen.
Rini
Brian I
BI
University of California San Francisco (UCSF) Comprehensive Cancer Center, USA. brini@medicine.ucsf.edu
Small
Eric J
EJ
D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D008297:Male; D017430:Prostate-Specific Antigen / Q000276:immunology; D011471:Prostatic Neoplasms / Q000628:therapy*
D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D019496:Cancer Vaccines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D017430:Prostate-Specific Antigen